McKinsey January 9, 2025
Guang Yang, Jeff Smith, with Emily Wingrove and Eva Lopez Vidal

Leading biopharmaceutical companies manage their clinical pipelines to optimize for risk and reward. Here’s how.

Discovering and developing effective new medicines has always been difficult—but it is particularly hard today. The world’s biopharmaceutical companies face challenges ranging from rising R&D costs to the evolving impact of the US Inflation Reduction Act, all while focused on delivering innovative solutions for patients. Yet leading companies remain effective despite these pressures, with the past few years seeing the emergence of innovative modalities and novel mechanisms of action (MoAs) that can better treat patients in areas with high levels of unmet medical needs. We examined what can be learned from their approaches and identified three actions leaders are taking to better position their portfolios:

...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, Pharma, Pharma / Biotech
FTC pauses PBM litigation in win for Caremark, Express Scripts, Optum Rx
Pharma Dodges The Tariff Bullet — But For How Long?
Noom, LillyDirect pharmacy provider partner to increase access to Zepbound
Robots can aid hospital pharmacies in safer and more sustainable cancer drug preparation
PBM Private Labeling Boosts Biosimilars, Raises Concerns

Share This Article